NCT03084926View on ClinicalTrials.gov

First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
Neoplasms
Interventions
DRUG

MP0274

Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons

Trial Locations (4)

Unknown

Study Site Frankfurt, Frankfurt

Study Site Heidelberg, Heidelberg

Study Site St. Gallen, Sankt Gallen

Study Site Cambridge, Cambridge

Sponsors
All Listed Sponsors
lead

Molecular Partners AG

INDUSTRY